XML 28 R11.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

COMMITMENTS AND CONTINGENCIES | 9 Months Ended
--- | ---
Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES |
COMMITMENTS AND CONTINGENCIES | E. COMMITMENTS AND CONTINGENCIES Clinical Research Agreement Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, Collaborative Arrangements. The Company determined the payments to Ergomed are within the scope of ASC 730, Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.9 million. During the nine months ended June 30, 2024 and 2023, the Company recorded, net of Ergomed’s discount, approximately $0.1 million for each period as research and development expense related to Ergomed’s services. During the three months ended June 30, 2024 the Company did not record any research and development expense related to Egromed’s services and during three months ended June 30, 2023, the Company recorded, net of Ergomed’s discount, less than $0.1 million as research and development expense related to Ergomed’s services. Lease Agreements The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain. The San Tomas lease is classified as a finance lease on the Company’s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the nine months ended June 30, 2024 and 2023 was approximately $2.0 and $1.9 million, respectively, of which approximately $0.7 and $0.8 million was for interest, respectively, in each nine-month period. As of June 30, 2024, the weighted average discount rate of the Company’s finance leases is 8.46% and the weighted average time to maturity is 4.34 years. On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year’s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. Approximate future minimum lease payments under finance leases as of June 30, 2024 are as follows:
Three months ending September 30, 2024 |  | $ | 666,000 |
Year ending September 30, |  |  |  |
2025 |  |  | 2,747,000 |
2026 |  |  | 2,838,000 |
2027 |  |  | 2,929,000 |
2028 |  |  | 3,021,000 |
2029 |  |  | 255,000 |
Total future minimum lease obligation |  |  | 12,456,000 |
Less imputed interest on finance lease obligations |  |  | (2,029,000 | )
Net present value of financing lease obligations |  |  | 10,427,000 |
Less net present value of financing lease obligations – current portion |  |  | (1,949,000 | )
Net present value of financing lease obligations - non-current portion |  | $ | 8,478,000 |
The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.3 million for both the nine months ended June 30, 2024 and 2023. Total cash paid related to operating leases during the nine months ended June 30, 2024 and 2023 was approximately $0.3 million for each period. The weighted average discount rate of the Company’s operating leases is 10.19% and the weighted average time to maturity is 7.16 years. As of June 30, 2024, approximate future minimum lease payments under operating leases are as follows:
Three months ending September 30, 2024 |  | $ | 90,000 |
Year ending September 30, |  |  |  |
2025 |  |  | 366,000 |
2026 |  |  | 287,000 |
2027 |  |  | 277,000 |
2028 |  |  | 285,000 |
2029 |  |  | 294,000 |
Thereafter |  |  | 746,000 |
Total future minimum lease obligation |  |  | 2,345,000 |
Less imputed interest on operating lease obligation |  |  | (640,000 | )
Net present value of operating lease obligations |  |  | 1,705,000 |
Less net present value of operating lease obligations - current portion |  |  | (219,000 | )
Net present value of operating lease obligations - non-current portion |  | $ | 1,486,000 |

X
- References No definition available. + Details
Name: | cvm_CommitmentsAndContingenciesAbstract
Namespace Prefix: | cvm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration